| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G03B2227-325 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate |
2002-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56217d5b43b15dfcc8c156160267957a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f71d048a4fdf1d463e4b00db1313a35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b664bfd82408bdeed04d16958534543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e65cc88645bda436827a530947fa9791
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c66f1553ae03350503caba7cd466c2a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6aa371bc78965c8abaf29ff7835eb0f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17db86d202234b3fed3efff5a4ec2b88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55c15e7e75950c8de8c0469529c88341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d6c8af068bf8fd0ada8a39023d344d4 |
| publicationDate |
2002-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2002119170-A1 |
| titleOfInvention |
Low toxicity drug-lipid systems |
| abstract |
Methods and compositions are described for nonliposomal lipid complexes in association with toxic hydrophobic drugs such as the polyene antibiotic amphotericin B. Lipid compositions are preferably a combination of the phospholipids dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) in about a 7:3 mole ratio. The lipid complexes contain a bioactive agent, and may be made by a number of procedures, at high drug:lipid ratios. These compositions of high drug:lipid complexes (HDLCs) may be administered to mammals such as humans for the treatment of infections, with substantially equivalent or greater efficacy and reduced drug toxicities as compared to the drugs in their free form. Also disclosed is a novel liposome-loading procedure, which may also be used in the formation of the HDLCs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007249546-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018156585-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017056113-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100832553-B1 |
| priorityDate |
1987-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |